Metagenomics combined with activity-based proteomics point to gut bacterial enzymes that reactivate mycophenolate
Mycophenolate mofetil (MMF) is an important immunosuppressant prodrug prescribed to prevent organ transplant rejection and to treat autoimmune diseases. MMF usage, however, is limited by severe gastrointestinal toxicity that is observed in approximately 45% of MMF recipients. The active form of the...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2022-12-01
|
| Series: | Gut Microbes |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/19490976.2022.2107289 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849688398417100800 |
|---|---|
| author | Joshua B. Simpson Josh J. Sekela Amanda L. Graboski Valentina B. Borlandelli Marissa M. Bivins Natalie K. Barker Alicia A. Sorgen Angie L. Mordant Rebecca L. Johnson Aadra P. Bhatt Anthony A. Fodor Laura E. Herring Hermen Overkleeft John R. Lee Matthew. R. Redinbo |
| author_facet | Joshua B. Simpson Josh J. Sekela Amanda L. Graboski Valentina B. Borlandelli Marissa M. Bivins Natalie K. Barker Alicia A. Sorgen Angie L. Mordant Rebecca L. Johnson Aadra P. Bhatt Anthony A. Fodor Laura E. Herring Hermen Overkleeft John R. Lee Matthew. R. Redinbo |
| author_sort | Joshua B. Simpson |
| collection | DOAJ |
| description | Mycophenolate mofetil (MMF) is an important immunosuppressant prodrug prescribed to prevent organ transplant rejection and to treat autoimmune diseases. MMF usage, however, is limited by severe gastrointestinal toxicity that is observed in approximately 45% of MMF recipients. The active form of the drug, mycophenolic acid (MPA), undergoes extensive enterohepatic recirculation by bacterial β-glucuronidase (GUS) enzymes, which reactivate MPA from mycophenolate glucuronide (MPAG) within the gastrointestinal tract. GUS enzymes demonstrate distinct substrate preferences based on their structural features, and gut microbial GUS enzymes that reactivate MPA have not been identified. Here, we compare the fecal microbiomes of transplant recipients receiving MMF to healthy individuals using shotgun metagenomic sequencing. We find that neither microbial composition nor the presence of specific structural classes of GUS genes are sufficient to explain the differences in MPA reactivation measured between fecal samples from the two cohorts. We next employed a GUS-specific activity-based chemical probe and targeted metaproteomics to identify and quantify the GUS proteins present in the human fecal samples. The identification of specific GUS enzymes was improved by using the metagenomics data collected from the fecal samples. We found that the presence of GUS enzymes that bind the flavin mononucleotide (FMN) is significantly correlated with efficient MPA reactivation. Furthermore, structural analysis identified motifs unique to these FMN-binding GUS enzymes that provide molecular support for their ability to process this drug glucuronide. These results indicate that FMN-binding GUS enzymes may be responsible for reactivation of MPA and could be a driving force behind MPA-induced GI toxicity. |
| format | Article |
| id | doaj-art-d7e2a86fc68a4383913bdd253fcb47e1 |
| institution | DOAJ |
| issn | 1949-0976 1949-0984 |
| language | English |
| publishDate | 2022-12-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Gut Microbes |
| spelling | doaj-art-d7e2a86fc68a4383913bdd253fcb47e12025-08-20T03:22:00ZengTaylor & Francis GroupGut Microbes1949-09761949-09842022-12-0114110.1080/19490976.2022.2107289Metagenomics combined with activity-based proteomics point to gut bacterial enzymes that reactivate mycophenolateJoshua B. Simpson0Josh J. Sekela1Amanda L. Graboski2Valentina B. Borlandelli3Marissa M. Bivins4Natalie K. Barker5Alicia A. Sorgen6Angie L. Mordant7Rebecca L. Johnson8Aadra P. Bhatt9Anthony A. Fodor10Laura E. Herring11Hermen Overkleeft12John R. Lee13Matthew. R. Redinbo14Department of Chemistry, University of North Carolina at Chapel Hill, Chapel Hill, NC, USADepartment of Chemistry, University of North Carolina at Chapel Hill, Chapel Hill, NC, USADepartment of Pharmacology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USADepartment of Bioorganic Synthesis, Leiden Institute of Chemistry, Leiden University, Leiden, The NetherlandsDepartment of Pharmacology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USAUNC Proteomics Core Facility, Department of Pharmacology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USADepartment of Biological Sciences, University of North Carolina at Charlotte, Charlotte, NC, USAUNC Proteomics Core Facility, Department of Pharmacology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USACenter for Integrative Chemical Biology and Drug Discovery, Division of Chemical Biology and Medicinal Chemistry, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC, USADivision of Gastroenterology and Hepatology, Department of Medicine, Center for Gastrointestinal Biology and Disease, and the Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USADepartment of Bioinformatics and Genomics, University of North Carolina at Charlotte, Charlotte, NC, USAUNC Proteomics Core Facility, Department of Pharmacology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USADepartment of Bioorganic Synthesis, Leiden Institute of Chemistry, Leiden University, Leiden, The NetherlandsDepartment of Medicine, Division of Nephrology and Hypertension, New York, New York, USADepartment of Chemistry, University of North Carolina at Chapel Hill, Chapel Hill, NC, USAMycophenolate mofetil (MMF) is an important immunosuppressant prodrug prescribed to prevent organ transplant rejection and to treat autoimmune diseases. MMF usage, however, is limited by severe gastrointestinal toxicity that is observed in approximately 45% of MMF recipients. The active form of the drug, mycophenolic acid (MPA), undergoes extensive enterohepatic recirculation by bacterial β-glucuronidase (GUS) enzymes, which reactivate MPA from mycophenolate glucuronide (MPAG) within the gastrointestinal tract. GUS enzymes demonstrate distinct substrate preferences based on their structural features, and gut microbial GUS enzymes that reactivate MPA have not been identified. Here, we compare the fecal microbiomes of transplant recipients receiving MMF to healthy individuals using shotgun metagenomic sequencing. We find that neither microbial composition nor the presence of specific structural classes of GUS genes are sufficient to explain the differences in MPA reactivation measured between fecal samples from the two cohorts. We next employed a GUS-specific activity-based chemical probe and targeted metaproteomics to identify and quantify the GUS proteins present in the human fecal samples. The identification of specific GUS enzymes was improved by using the metagenomics data collected from the fecal samples. We found that the presence of GUS enzymes that bind the flavin mononucleotide (FMN) is significantly correlated with efficient MPA reactivation. Furthermore, structural analysis identified motifs unique to these FMN-binding GUS enzymes that provide molecular support for their ability to process this drug glucuronide. These results indicate that FMN-binding GUS enzymes may be responsible for reactivation of MPA and could be a driving force behind MPA-induced GI toxicity.https://www.tandfonline.com/doi/10.1080/19490976.2022.2107289Multi-OmicsMetagenomicsProteomicsMetaproteomicsMicrobiomeGlycoside Hyrolase |
| spellingShingle | Joshua B. Simpson Josh J. Sekela Amanda L. Graboski Valentina B. Borlandelli Marissa M. Bivins Natalie K. Barker Alicia A. Sorgen Angie L. Mordant Rebecca L. Johnson Aadra P. Bhatt Anthony A. Fodor Laura E. Herring Hermen Overkleeft John R. Lee Matthew. R. Redinbo Metagenomics combined with activity-based proteomics point to gut bacterial enzymes that reactivate mycophenolate Gut Microbes Multi-Omics Metagenomics Proteomics Metaproteomics Microbiome Glycoside Hyrolase |
| title | Metagenomics combined with activity-based proteomics point to gut bacterial enzymes that reactivate mycophenolate |
| title_full | Metagenomics combined with activity-based proteomics point to gut bacterial enzymes that reactivate mycophenolate |
| title_fullStr | Metagenomics combined with activity-based proteomics point to gut bacterial enzymes that reactivate mycophenolate |
| title_full_unstemmed | Metagenomics combined with activity-based proteomics point to gut bacterial enzymes that reactivate mycophenolate |
| title_short | Metagenomics combined with activity-based proteomics point to gut bacterial enzymes that reactivate mycophenolate |
| title_sort | metagenomics combined with activity based proteomics point to gut bacterial enzymes that reactivate mycophenolate |
| topic | Multi-Omics Metagenomics Proteomics Metaproteomics Microbiome Glycoside Hyrolase |
| url | https://www.tandfonline.com/doi/10.1080/19490976.2022.2107289 |
| work_keys_str_mv | AT joshuabsimpson metagenomicscombinedwithactivitybasedproteomicspointtogutbacterialenzymesthatreactivatemycophenolate AT joshjsekela metagenomicscombinedwithactivitybasedproteomicspointtogutbacterialenzymesthatreactivatemycophenolate AT amandalgraboski metagenomicscombinedwithactivitybasedproteomicspointtogutbacterialenzymesthatreactivatemycophenolate AT valentinabborlandelli metagenomicscombinedwithactivitybasedproteomicspointtogutbacterialenzymesthatreactivatemycophenolate AT marissambivins metagenomicscombinedwithactivitybasedproteomicspointtogutbacterialenzymesthatreactivatemycophenolate AT nataliekbarker metagenomicscombinedwithactivitybasedproteomicspointtogutbacterialenzymesthatreactivatemycophenolate AT aliciaasorgen metagenomicscombinedwithactivitybasedproteomicspointtogutbacterialenzymesthatreactivatemycophenolate AT angielmordant metagenomicscombinedwithactivitybasedproteomicspointtogutbacterialenzymesthatreactivatemycophenolate AT rebeccaljohnson metagenomicscombinedwithactivitybasedproteomicspointtogutbacterialenzymesthatreactivatemycophenolate AT aadrapbhatt metagenomicscombinedwithactivitybasedproteomicspointtogutbacterialenzymesthatreactivatemycophenolate AT anthonyafodor metagenomicscombinedwithactivitybasedproteomicspointtogutbacterialenzymesthatreactivatemycophenolate AT lauraeherring metagenomicscombinedwithactivitybasedproteomicspointtogutbacterialenzymesthatreactivatemycophenolate AT hermenoverkleeft metagenomicscombinedwithactivitybasedproteomicspointtogutbacterialenzymesthatreactivatemycophenolate AT johnrlee metagenomicscombinedwithactivitybasedproteomicspointtogutbacterialenzymesthatreactivatemycophenolate AT matthewrredinbo metagenomicscombinedwithactivitybasedproteomicspointtogutbacterialenzymesthatreactivatemycophenolate |